Benzinga
11 Nov 2025, 16:40 UTC · 51w ago
Organon Analysts Cut Their Forecasts Following Q3 Results
Impact · against what's priced in
Organon's stock is under pressure as the company lowered its fiscal sales guidance to $6.20 billion - $6.25 billion, missing previous consensus. While Q3 earnings and sales beat expectations, the downward revision to the full-year outlook outweighs the short-term operational beat.
- OGN−0.40
No priced-in read yet
- In context
The company's decision to lower fiscal sales guidance to a range of $6.20 billion to $6.25 billion, which is below the $6.289 billion consensus, outweighs the Q3 adjusted earnings beat of $1.01 per share.
Read from the article alone
